Baseline comorbidities in patients with rheumatoid arthritis who have been prescribed biological therapy: A case control study

Reumatologia Clinica

Volumn 9, Issue 1, 2013, Pages 18-23

  Espiño Lorenzo, Pilar ^a   Manrique Arija, Sara ^a   Ureña, Inmaculada ^a   Jiménez Núñez, Francisco Gabriel ^a   López Lasanta, María ^a   Romero Barco, Carmen María ^a   Belmonte López, María Angeles ^a   Irigoyen, María Victoria ^a   Fernández Nebro, Antonio ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Anti TNF ; Biological therapy; Comorbidity; Rheumatoid arthritis

Indexed keywords

ANTIMALARIAL AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID;

ADULT; AGED; ARTHROPLASTY; ARTICLE; BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DISEASE CONTROL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRESCRIPTION; RESPIRATORY TRACT DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; THYROID DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMORBIDITY; FEMALE; HUMANS; IMMUNOGLOBULIN G; LOGISTIC MODELS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872817820     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2012.05.012     Document Type: Article

References (40)

1. Carmona L., Villaverde V., Hernandez-Garcia C., Ballina J., Gabriel R., Laffon A. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford) 2002, 41:88-95. [Epub 17.01.02].
2. Carbonell J., Cobo T., Balsa A., Descalzo M.A., Carmona L. The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. Rheumatology (Oxford) 2008, 47:1088-1092. [Epub 31.05.08].
3. Lajas C., Abasolo L., Bellajdel B., Hernandez-Garcia C., Carmona L., Vargas E., et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 2003, 49:64-70. [Epub 13.02.03].
4. Michaud K., Wolfe F. Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007, 21:885-906. Epub 2007/09/18.
5. Verbrugge L.M., Gates D.M., Ike R.W. Risk factors for disability among U.S. adults with arthritis. J Clin Epidemiol 1991, 44:167-182. [Epub 01.01.91].
6. Gabriel S.E., Crowson C.S., O'Fallon W.M. Comorbidity in arthritis. J Rheumatol 1999, 26:2475-2479. [Epub 11.11.99].
7. Hyrich K., Symmons D., Watson K., Silman A. Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis 2006, 65:895-898. [Epub 13.12.05].
8. Goodson N., Marks J., Lunt M., Symmons D. Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 2005, 64:1595-1601. [Epub 22.04.05].
9. Choi H.K., Hernan M.A., Seeger J.D., Robins J.M., Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359:1173-1177. [Epub 17.04.02].
10. Fernandez-Nebro A., Irigoyen M.V., Urena I., Belmonte-Lopez M.A., Coret V., Jimenez-Nunez F.G., et al. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-Naive rheumatoid arthritis. J Rheumatol 2007, 34:2334-2342.
11. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. [Epub 01.03.88].
12. Gomez-Reino J.J., Carmona L., Valverde V.R., Mola E.M., Montero M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48:2122-2127. [Epub 09.08.03].
13. Greenfield S., Apolone G., McNeil B.J., Cleary P.D. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Med Care 1993, 31:141-154. [Epub 01.02.93].
14. van der Heijde D.M., Jacobs J.W. The original DAS and the DAS28 are not interchangeable: comment on the articles by Prevoo et al. Arthritis Rheum 1998, 41:942-945. [Epub 20.05.98].
15. Prevoo M.L., van't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48. [Epub 01.01.95].
16. Kroot E.J., van Leeuwen M.A., van Rijswijk M.H., Prevoo M.L., Van't Hof M.A., van De Putte L.B., et al. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann Rheum Dis 2000, 59:954-958. [Epub 23.11.2000].
17. Esteve-Vives J., Batlle-Gualda E., Reig A. Spanish version of the Health Assessment Questionnaire: reliability, validity and transcultural equivalency. Grupo para la Adaptacion del HAQ a la Poblacion Espanola. J Rheumatol 1993, 20:2116-2122. [Epub 01.12.93].
18. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497. [Epub 23.05.01].
19. Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Sherwin R., et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006, 49:1711-1721. [Epub 28.06.06].
20. Hu G., Tuomilehto J., Borodulin K., Jousilahti P. The joint associations of occupational, commuting, and leisure-time physical activity, and the Framingham risk score on the 10-year risk of coronary heart disease. Eur Heart J 2007, 28:492-498.
21. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383. [Epub 01.01.87].
22. DeMaria A.N. Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J Cardiol 2002, 89:33D-38D. [Epub 23.03.02].
23. Curtis J.R., Jain A., Askling J., Bridges S.L., Carmona L., Dixon W., et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010, 40. 2-14e1 [Epub 01.08.10].
24. Carmona L., Gonzalez-Alvaro I., Balsa A., Angel Belmonte M., Tena X., Sanmarti R. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis 2003, 62:897-900. [Epub 19.08.03].
25. Kapetanovic M., Lindqvist E., Simonsson M., Geborek P., Saxne T., Eberhardt K. Prevalence and predictive factors of comorbidity in rheumatoid arthritis patients monitored prospectively from disease onset up to 20 years: lack of association between inflammation and cardiovascular disease. Scand J Rheumatol 2010, 39:353-359.
26. Svenson K.L., Lithell H., Hallgren R., Selinus I., Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity. Arch Intern Med 1987, 147:1912-1916. [Epub 01.11.87].
27. Park Y.B., Lee S.K., Lee W.K., Suh C.H., Lee C.W., Lee C.H., et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999, 26:1701-1704. [Epub 18.08.99].
28. Fortin M., Bravo G., Hudon C., Vanasse A., Lapointe L. Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med 2005, 3:223-228.
29. Hyrich K.L., Silman A.J. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety. J Rheumatol 2006, 33:831-833. [Epub 03.05.06].
30. Rupp I., Boshuizen H.C., Jacobi C.E., Dinant H.J., van den Bos G. Comorbidity in patients with rheumatoid arthritis: effect on health-related quality of life. J Rheumatol 2004, 31:58-65. [Epub 06.01.04].
31. Westhovens R., Yocum D., Han J., Berman A., Strusberg I., Geusens P., et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006, 54:1075-1086. [Epub 31.03.06].
32. Caporali R., Cimmino M.A., Sarzi-Puttini P., Scarpa R., Parazzini F., Zaninelli A., et al. Comorbid conditions in the AMICA study patients: effects on the quality of life and drug prescriptions by general practitioners and specialists. Semin Arthritis Rheum 2005, 35(Suppl. 1):31-37. [Epub 09.08.05].
33. Loza E., Jover J.A., Rodriguez-Rodriguez L., Carmona L. Observed and expected frequency of comorbid chronic diseases in rheumatic patients. Ann Rheum Dis 2008, 67:418-421. [Epub 06.11.07].
34. Gabriel S.E., Crowson C.S., O'Fallon W.M. A comparison of two comorbidity instruments in arthritis. J Clin Epidemiol 1999, 52:1137-1142. [Epub 02.12.99].
35. Van Doornum S., McColl G., Wicks I. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis. Arthritis Rheum 2002, 46:862-873.
36. Sattar N., McCarey D.W., Capell H., McInnes I.B. Explaining how high-grade systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003, 108:2957-2963. [Epub 17.12.03].
37. Jacobsson L.T., Turesson C., Nilsson J.A., Petersson I.F., Lindqvist E., Saxne T., et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66:670-675. [Epub 13.12.06].
38. Naranjo A., Sokka T., Descalzo M.A., Calvo-Alen J., Horslev-Petersen K., Luukkainen R.K., et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008, 10:R30. [Epub 08.03.08].
39. Radovits B.J., Fransen J., Al Shamma S., Eijsbouts A.M., van Riel P.L., Laan R.F. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010, 62:362-370. [Epub 15.04.10].
40. Wolfe F., Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008, 58:2612-2621. [Epub 02.09.08].